文献速递胸部肿瘤支持与姑息治疗

癌症合并COVID-19患者的生命延长治疗限制与结局:荷兰肿瘤COVID-19联盟更新分析

Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.
PubMed 文献 · Eur J Cancer · 2021-10-25

荷兰45家医院注册研究纳入830例可验证的癌症合并COVID-19患者,27.7%死于COVID-19,其余600例中60%住院。血液肿瘤或肺癌患者死亡风险高于其他实体瘤,抗癌治疗与致命结局无相关性,50%患者存在生命延长治疗限制。

要点

  • 830例癌症合并COVID-19患者中27.7%死于COVID-19,其余600例中60%住院。
  • 血液肿瘤或肺癌患者致死性结局风险高于其他实体瘤。
  • 未发现抗癌治疗与致命COVID-19结局风险之间存在相关性。

核心结论

  • 未发现抗癌治疗对COVID-19结局有负面影响的证据。
  • 及时进行作为预立医疗照护计划一部分的临终沟通可使患者免受长期痛苦并减轻重症监护病房负担。
  • 早期讨论治疗限制应成为常规肿瘤诊疗的一部分,尤其在COVID-19大流行期间。

研究设计与样本

  • 荷兰肿瘤COVID-19联盟注册研究于2020年3月在荷兰45家医院启动,主要目的是识别癌症患者发生重症COVID-19结局的危险因素。
  • 本次为注册研究的更新分析,研究治疗限制(如不予插管指令)与癌症患者COVID-19结局的关系,未考虑肿瘤治疗限制。
  • 2020年3月27日至2021年2月4日期间注册1360例癌症合并COVID-19患者,其中830例的随访数据可验证并纳入本分析。

主要发现

  • 830例患者中230例(27.7%)死于COVID-19,其余600例COVID-19已消退的患者中60%曾住院。
  • 血液肿瘤或肺癌患者致死性结局风险高于其他实体瘤。
  • 未发现抗癌治疗与致命COVID-19结局风险之间存在相关性。
  • 所有患者中50%存在关于生命延长治疗的限制(如不予插管指令)。
  • 大多数被识别出存在治疗限制的患者具有与致命COVID-19结局相关的危险因素。

临床怎么用

  • 作者认为,及时进行作为预立医疗照护计划一部分的临终沟通可使患者免受长期痛苦并减轻重症监护病房负担。
  • 作者建议,早期讨论治疗限制应成为常规肿瘤诊疗的一部分,尤其在COVID-19大流行期间。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM OF THE STUDY: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied in patients with cancer and COVID-19. METHODS: The Dutch Oncology COVID-19 Consortium registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g. do-not-intubate codes) were studied in relation to COVID-19 outcomes in patients with cancer. Oncological treatment restrictions were not taken into account. RESULTS: Between 27th March 2020 and 4th February 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anticancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g. do-not-intubate codes). Most identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome. CONCLUSION: There was no evidence of a negative impact of anticancer therapies on COVID-19 outcomes. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. de Joode K, Tol J, Hamberg P, et al. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer. 2021. PMID: 34799210. doi:10.1016/j.ejca.2021.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。